 "Mergers and acquisitions, M&A, deals")
Hyderabad-based biotechnology company BioVaram on Thursday said it has signed a MoU with Japan's Teijin Limited to collaborate on expanding usage of Regenerative Medicine products and Implantable medical devices in Japan and India.
BioVaram, the University of Hyderabad incubated startup, is the brand name of the UR Advanced Therapeutics Pvt Ltd (URAT), a release said.
The collaboration aims to expand the reach of Teijin Group's implantable medical devices and regenerative medicine products in India, while also introducing BioVaram's advanced product portfolio to the Japanese market, it said.
"Under the terms of the agreement, Teijin and BioVaram will explore the regulatory approval and commercialisation of SYNFOLIUM?, a cardiovascular repair patch by Teijin Medical Technologies Co, Ltd, in India," it said.
The collaboration will open up opportunities for expanding use of Japan Tissue Engineering Co, Ltd's (part of the Teijin Group) regenerative medicine products in India.
Also Read
 "Sanae Takaichi, Japan PM")
 "tsunami")
 "Japan earthquake")
 "Subhas Chandra Bose, Anime")
 "S Jaishankar, Jaishankar")
The agreement will also lead to the development and commercialisation in Japan of BioVaram technologies, including exosome-based diagnostics and therapeutics, Extracellular Matrix mimics, and bio-derived materials such as Type I atelocollagen.
According to Takayuki Nakano, Mission Executive and General Manager, Regenerative Medicine & Implantable Medical Device Division of Teijin Limited: "The partnership with UR Advanced Therapeutics marks a highly significant step toward Teijin's global expansion in the fields of regenerative medicine and implantable medical devices." UR Advanced Therapeutics Founder and CEO Jaganmohan Reddy said the MoU with Teijin Limited reinforces BioVaram's vision to build transformative biotech innovations in India together with global partners.
"This partnership strengthens our capabilities in research, innovation, and scalable manufacturing of advanced tissue engineering products, while enabling Teijin to take BioVaram's products to global markets," he said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
 "The much-anticipated provision of the deal value threshold (DVT) under the Competition Amendment Act 2023, notified on Monday, seeks to capture mergers and acquisitions (M&As) where the deal value exceeds Rs 2,000 crore or where the target company ha")
 "Rs, Rupee, Indian Currency")
 "Enforcement Directorate, ED")
 "figma")
 "Bima Sugam, insurance, life insurance, health insurance, group insurance")
